Sofwave Medical (TASE: SOFW) on Non-Invasive Aesthetics, GLP-1 Tailwinds and 2026 Growth Strategy

Why It Matters

High recurring revenue, strong gross margins and a clear demand tailwind (including GLP-1 effects) give Sofwave a capital-efficient growth profile that could amplify returns if utilization continues to scale. Investors should watch pulse adoption and international market expansion as key catalysts for 2026 performance.

Summary

Sofwave Medical, founded in 2016, sells a high-frequency ultrasound platform for non-invasive skin lifting and tightening with nine FDA clearances and a new muscle-toning product. The company reported nearly $90 million in revenue last year, is profitable, and derives about 45% of sales from recurring “pulse” utilization, which management says is its fastest-growing, highest-margin segment. Sofwave touts consistent, durable results across skin types and cites a secular demand surge driven in part by GLP-1-related facial and body changes. Management highlights prior >40% annual revenue growth and gross margins above 75% as foundations for its 2026 growth strategy.

Original Description

In this interview, Louis Scafuri, CEO of Sofwave Medical (TASE: SOFW), discusses the company's innovative non-invasive aesthetic solutions, their unique technology, market positioning, and key growth catalysts for 2026.

Chapters:

00:00 Introduction to Sofwave Medical

02:03 Unique Technologies and Market Positioning

04:05 Mechanism of Action and Treatment Benefits

06:12 Background and Experience of Louis Scafuri

07:01 Key Value Catalysts for 2026

Sofwave Medical will be presenting at the upcoming Planet MicroCap Las Vegas 2026 powered by MicroCapClub. Register to attend here: https://www.meetmax.com/sched/event_130817/conference_home.html

For more information about Sofwave Medical, please visit: https://sofwave.com/

The interview may contain forward looking statements about Sofwave Medical. See Sofwave Medical's periodic filings with the Tel Aviv Stock Exchange for more complete information.

About Sofwave Medical

Sofwave Medical is home to Sofwave® and Pure Impact® VIP, two FDA-cleared, non-invasive technologies designed to improve skin quality and muscle tone without surgery or downtime. Sofwave® uses proprietary SUPERB™ ultrasound technology to target the mid-dermis, improving skin laxity and delivering visible lifting to the brow, under the chin, the neck, and arms. Safe for all skin types, most patients see optimal results in 1–2 treatments. Pure Impact® VIP uses proprietary PlyoPulse™ technology to strengthen and tone muscles through multi-directional electrical stimulation that mimics functional exercise, activating multiple muscle groups in a single 30-minute session. Together, the platforms offer a science-backed, non-invasive approach to skin and muscle rejuvenation with no surgery, needles, or downtime.

Planet Microcap hosts the highest quality in-person microcap events in North America. The mission is to bring the best microcap investors, companies, and allocators together to gather, connect, and grow.; visit https://planetmicrocap.com/ to learn more about our Las Vegas and Toronto events.

This presentation is for informational purposes only and should not be construed as a recommendation to purchase or sell any security referenced herein. Planet MicroCap Holdings LLC and MicroCapClub LLC (collectively, “we” or “our”) are not licensed brokers nor registered investment advisors. We, our partners, contractors, members, subscribers, guests, or affiliates may or may not hold positions in one or more of the securities mentioned in this presentation and may trade in such securities at any time. We may have received cash compensation from one or more participants for presenting at past, present, or future events. We recommend you consult a licensed investment adviser, broker, or legal counsel before purchasing or selling any securities referenced in this presentation.